form8k_063009.htm

0001168220-09-000037.txt : 20090630 0001168220-09-000037.hdr.sgml : 20090630 20090630093036 ACCESSION NUMBER: 0001168220-09-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20090630 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20090630 DATE AS OF CHANGE: 20090630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ULURU INC. CENTRAL INDEX KEY: 0001168220 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 412118656 STATE OF INCORPORATION: NV FISCAL YEAR END: 1205 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33618 FILM NUMBER: 09917992 BUSINESS ADDRESS: STREET 1: 4452 BELTWAY DRIVE CITY: ADDISON STATE: TX ZIP: 75001 BUSINESS PHONE: 214-905-5145 MAIL ADDRESS: STREET 1: 4452 BELTWAY DRIVE CITY: ADDISON STATE: TX ZIP: 75001 FORMER COMPANY: FORMER CONFORMED NAME: OXFORD VENTURES INC DATE OF NAME CHANGE: 20020225 8-K 1 form8k_063009.htm FORM 8-K 06/30/2009 form8k_063009.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 30, 2009

ULURU Inc.

(Exact Name of Registrant as Specified in its Charter)


Nevada	000-49670	41-2118656
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4452 Beltway Drive

Addison, Texas 75001

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (214) 905-5145

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01	Regulation FD Disclosure.

On June 30, 2009, ULURU Inc., a Nevada corporation (the “Company”), announced that it has restructured its operations to reflect a revised business plan that is being implemented in efforts to conserve the necessary cash to further the Company’s business.

A copy of a press release issued by the Company regarding the items described above is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01	Financial Statements and Exhibits

(d)	Exhibits

Exhibit No.	Description
99.1	Press Release dated June 30, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ULURU Inc.

Date: June 30, 2009	By:	/s/ Terrance K. Wallberg
		Terrance K. Wallberg
		Vice President and Chief Financial Officer

EXHIBIT INDEX


Exhibit No.	Description
99.1	Press Release dated June 30, 2009.

EX-99.1 2 ex_99-1.htm PRESS RELEASE DATED 06/30/2009 ex_99-1.htm

ULURU NEWS

Contact: Company

Renaat E. Van den Hooff

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145

ULURU INC. ANNOUNCES REVISED BUSINESS PLAN

Addison, Texas, June 30, 2009; ULURU Inc. (NYSE AMEX: ULU) ULURU Inc. today announced that it has restructured its operations in efforts to conserve the necessary cash to further the Company’s business.

During the past 12 months we have generated significant clinical data that has demonstrated the advantages of using Altrazeal™ in many wound settings. To effectively market Altrazeal™ to the numerous practitioners and sites of care it has been determined that significantly greater sales and marketing resources are required. Consequently, it has been determined that the Company can more effectively maximize the revenue potential of Altrazeal™ through a strategic relationship. With the extensive clinical data and successful patient outcomes that have been generated since the launch of Altrazeal™, we believe that we are in a strong position to execute on this strategic objective.

Moving forward a core management group will be supplemented by a small selection of external consultants to support our business activities. Selling efforts will continue through a network of independent sales reps.

The Company will now focus exclusively on its wound care products and technology. Non-core assets that are outside this focus will be divested.

ULURU has engaged Rodman & Renshaw, LLC to assist the Company with a number of strategic initiatives including potential strategic partnerships and fund raising.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and transmucosal delivery system. For more information about Altrazeal™, please visit www.Altrazeal™.com. For more information about ULURU Inc., please visit www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the company’s clinical results and the company’s restructuring and planned sale of non-strategic assets. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.